MolDX: Melanoma Risk Stratification Molecular Testing (L37748) - R8 - Effective June 26, 2025

Date Posted: October 16, 2025

This MolDX Local Coverage Determination (LCD) has been revised under contract numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).

Effective Date: June 26, 2025

Summary of Changes:

Under Summary of Evidence Paragraph 5 updated sentence "Importantly, the 5-year melanoma specific survival (MSS) rate for T1/T2 low-risk group remains favorable; with 99% MSS, comparable to that observed in T1a tumors and for which current guidelines do not recommend SLNB. 2,27" Updated Bibliography Reference #19.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCD or access it via the CMS Medicare Coverage Database (MCD).

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )